ATP6V0D2

Across TCGA pan-cancer cohorts, ATP6V0D2 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of ATP6V0D2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ATP6V0D2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ATP6V0D2 is over-expressed in tumor, although a few such as CCRCC and LUAD show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where ATP6V0D2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATP6V0D2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−1.256	<.001	11	view →
LUAD	Male	All	−0.591	<.001	7	view →
LSCC	Male	All	−0.552	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

ATP6V0D2–CCRCC

Open the CCRCC breakdown →